Selected article for: "camel distribution and current camel distribution"
Author: Crameri, Gary; Durr, Peter A.; Barr, Jennifer; Yu, Meng; Graham, Kerryne; Williams, Owen J.; Kayali, Ghazi; Smith, David; Peiris, Malik; Mackenzie, John S.; Wang, Lin-Fa
Title: Absence of MERS-CoV antibodies in feral camels in Australia: Implications for the pathogen's origin and spread
  • Document date: 2015_11_2
    • ID: yxtepbta_5
    Snippet: As a first step toward a risk assessment of potential bat-to-camel transmission of MERS-CoV like pathogens in Australia, we examined the current camel distribution in Australia and its overlap with the habitat of native bat species related to those from which MERS-CoV-like viruses have been detected. Furthermore, we conducted a MERS-CoV sero-prevalence study on more than 300 camel serum samples collected from three different locations at four tim.....
    Document: As a first step toward a risk assessment of potential bat-to-camel transmission of MERS-CoV like pathogens in Australia, we examined the current camel distribution in Australia and its overlap with the habitat of native bat species related to those from which MERS-CoV-like viruses have been detected. Furthermore, we conducted a MERS-CoV sero-prevalence study on more than 300 camel serum samples collected from three different locations at four time points from December 2013 to August 2014.

    Search related documents:
    Co phrase search for related documents
    • camel bat and MERS cov: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • camel bat transmission and MERS cov: 1, 2
    • camel distribution and MERS cov: 1, 2, 3
    • camel serum and MERS cov: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • different location and MERS cov: 1, 2, 3
    • different location and risk assessment: 1
    • different location and time point: 1
    • MERS cov and risk assessment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • MERS cov and sero prevalence: 1, 2
    • MERS cov and sero prevalence study: 1
    • MERS cov and time point: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • risk assessment and sero prevalence: 1
    • risk assessment and time point: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14